Earendil Labs signed a global license and development pact with WuXi XDC to access payload‑linker and CMC capabilities for ADC programs, a deal valued at up to approximately $885 million including milestones. Earendil will lead product development and regulatory submissions while WuXi XDC provides payload‑linker technology, manufacturing, and potential royalties. The collaboration highlights continued outsourcing and industrial partnerships to de‑risk ADC CMC and accelerate clinical development at scale.